Repligen Co. (NASDAQ:RGEN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Repligen Co. (NASDAQ:RGEN) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $181.00.

RGEN has been the topic of several recent analyst reports. Canaccord Genuity Group increased their target price on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday, February 21st. Royal Bank of Canada increased their target price on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, February 21st. Wolfe Research initiated coverage on Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating on the stock. JPMorgan Chase & Co. increased their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Finally, Canaccord Genuity Group initiated coverage on Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock.

Hedge Funds Weigh In On Repligen

Institutional investors have recently bought and sold shares of the stock. Signaturefd LLC raised its holdings in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 124 shares during the period. Sava Infond d.o.o. bought a new position in Repligen in the 4th quarter worth $29,000. Raiffeisen Bank International AG bought a new position in Repligen in the 4th quarter worth $29,000. Resources Management Corp CT ADV bought a new position in Repligen in the 3rd quarter worth $37,000. Finally, Quarry LP raised its holdings in Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 239 shares during the period. 97.64% of the stock is owned by institutional investors.

Repligen Stock Down 2.8 %

Shares of NASDAQ:RGEN opened at $155.70 on Monday. Repligen has a 52-week low of $113.50 and a 52-week high of $203.13. The firm has a market capitalization of $8.72 billion, a P/E ratio of -305.29, a P/E/G ratio of 4.54 and a beta of 0.95. The stock has a 50 day moving average price of $157.23 and a 200-day moving average price of $148.59. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, equities research analysts anticipate that Repligen will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.